SF Healthcare Week: The Co-Founder and CEO of Kardigan talks about this week's $300M series A financing to do precision medicine for cardiovascular disease
Tassos Gianakakos describes the round and the investors who participated in it, and hints at the personalized, biomarker driven approach that Kardigan will have to developing medicines that benefit a wider percentage of the population than today's 'one size fits all' approach to this area.